This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Cytophage Technologies Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Steven Theriault
Chief executive officer
CA$350.0k
Total compensation
CEO salary percentage
100.00%
CEO tenure
2.3yrs
CEO ownership
0.2%
Management average tenure
no data
Board average tenure
no data
Recent management updates
Recent updates
CEO Compensation Analysis
How has Steven Theriault's remuneration changed compared to Cytophage Technologies's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
n/a
n/a
-CA$4m
Sep 30 2025
n/a
n/a
-CA$5m
Jun 30 2025
n/a
n/a
-CA$5m
Mar 31 2025
n/a
n/a
-CA$5m
Dec 31 2024
CA$350k
CA$350k
-CA$8m
Sep 30 2024
n/a
n/a
-CA$8m
Jun 30 2024
n/a
n/a
-CA$8m
Mar 31 2024
n/a
n/a
-CA$8m
Dec 31 2023
CA$490k
CA$350k
-CA$5m
Dec 31 2022
CA$350k
CA$350k
-CA$4m
Compensation vs Market: Steven's total compensation ($USD250.25K) is below average for companies of similar size in the German market ($USD442.56K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Theriault
2.3yrs
Tenure
CA$350,000
Compensation
Dr. Steven Theriault, B.Sc., M.Sc., Ph D., is the Chief Executive Officer, Chief Science Officer, and Director of Cuspis Capital III Ltd. (formerly known as Cytophage Technologies Inc.). Dr. Theriault is a...
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/12 09:03
End of Day Share Price
2026/05/25 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytophage Technologies Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.